WEGO Health throws Ning network users a lifeline with sponsorship

Share this article:
WEGO Health is sponsoring all health networks at social networking platform Ning.com, enabling a million Ning network users to go on posting free of charge as the company phases out its free networks.

The one-year deal will provide Ning Plus service to users of Ning networks like People Living with Sickle Cell, which was started two years ago by WEGO user Ade Adeyokunnu.

“I'm a member of WEGO Health's network of health activists, and it's been a great way to connect with and learn from other people like me who build health communities,” said Adeyokunnu in a release. “I started People Living with Sickle Cell on Ning two years ago to give sickle cell disease patients and caregivers a place to meet and talk about what we're all going through, so I'm really glad they'll be able to continue to grow and thrive on Ning.”

The sponsorship gives Ning networks unlimited membership, full branding controland the ability to create groups, chats and events, along with access to WEGO's community of health activists, the firm said. WEGO will work over the next year “with other industry leaders to fund the expansion and extension of this sponsorship.” Ning recently announced a similar sponsorship by Pearson Publishing of education-focused Ning networks.

“The health networks built on Ning are a powerful example of health activists at work,” said WEGO CEO Jack Barrette, “and we're thrilled to be able to extend our mission through this sponsorship. We look forward to collaborating with health-focused Ning network creators to expand their reach and impact.”

Ning, a potential competitor to Facebook and MySpace that allows users to construct social networks around topics or areas of interest, announced in April amid a sharp downsizing that it was cutting its free networks loose to focus on its paid networks.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...